Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells

Virology Journal

Ad P Koets³  Lonneke Vervelde¹  Reina Sikkema³  Jeroen Hoeboer³  Willem J C Swinkels² 

[1]The Roslin Institute, Edinburgh University, Edinburgh, UK

[2]Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584, Utrecht, CL, The Netherlands

[3]Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584, Utrecht, CL, The Netherlands

关键词: Peptide Vaccination;    M2;    Chicken;    Influenza;   

Others  :  1149462
DOI  :  10.1186/1743-422X-10-206

 received in 2012-10-12, accepted in 2013-06-17,  发布年份 2013

【 摘 要 】

Background

Influenza viruses are characterized by their highly variable surface proteins HA and NA. The third surface protein M2 is a nearly invariant protein in all Influenza A strains. Despite extensive studies in other animal models, this study is the first to describe the use of recombinant M2 protein and a peptide coding for the extracellular part of the M2 protein (M2e) to vaccinate poultry.

Methods

Four groups of layer chickens received a prime-boost vaccination with recombinant M2 protein, M2e, a tetrameric construct from M2e peptide bound to streptavidin and a control tetrameric construct formulated with Stimune adjuvant.

Results

We determined the M2-specific antibody (Ab) responses in the serum before vaccination, three weeks after vaccination and two weeks after booster, at days 21, 42 and 56 of age. The group vaccinated with the M2 protein in combination with Stimune adjuvant showed a significant Ab response to the complete M2 protein as compared to the other groups. In addition an increased Ab response to M2e peptide was found in the group vaccinated with the M2e tetrameric construct. None of the vaccinated animals showed seroconversion to AI in a commercial ELISA. Finally no Ab’s were found that bound to M2 expressed on in vitro AI infected MDCK cells.

Conclusion

Although Ab’s are formed against the M2 protein and to Streptavidin bound M2e peptide in a tetrameric conformation these Ab’s do not recognize of M2 on the virus or on infected cells.

【 授权许可】

   
2013 Swinkels et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y: Evolution and ecology of influenza a viruses. Microbiol Rev 1992, 56:152-179.
• [2]Nayak DP, Hui EK, Barman S: Assembly and budding of influenza virus. Virus Res 2004, 106:147-165.
• [3]Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, et al.: Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
• [4]De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W: Universal influenza a vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
• [5]Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W: A universal influenza a vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
• [6]Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, et al.: Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
• [7]Zebedee SL, Lamb RA: Influenza a virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
• [8]Gotch F, McMichael A, Smith G, Moss B: Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 1987, 165:408-416.
• [9]Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W: Influenza a virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3:102. BioMed Central Full Text
• [10]Jameson J, Cruz J, Ennis FA: Human cytotoxic T-lymphocyte repertoire to influenza a viruses. J Virol 1998, 72:8682-8689.
• [11]Wu F, Huang JH, Yuan XY, Huang WS, Chen YH: Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
• [12]Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ: Protection of mice against influenza a virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
• [13]Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L Jr, Gerhard W: Induction of influenza type a virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
• [14]Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K, et al.: Protective immunity against influenza a virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001, 19:3681-3691.
• [15]Watabe S, Xin KQ, Ihata A, Liu LJ, Honsho A, Aoki I, Hamajima K, Wahren B, Okuda K: Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 2001, 19:4434-4444.
• [16]Frace AM, Klimov AI, Rowe T, Black RA, Katz JM: Modified M2 proteins produce heterotypic immunity against influenza a virus. Vaccine 1999, 17:2237-2244.
• [17]Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X: M2e-Based universal influenza a vaccine. Vaccine 2009, 27:6280-6283.
• [18]Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT: Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza a virus. J Gen Virol 2002, 83:1851-1859.
• [19]Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, Kehrli ME Jr, Roth JA: Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 2011, 29:2712-2719.
• [20]Kitikoon P, Vincent AL, Janke BH, Erickson B, Strait EL, Yu S, Gramer MR, Thacker EL: Swine influenza matrix 2 (M2) protein contributes to protection against infection with different H1 swine influenza virus (SIV) isolates. Vaccine 2009, 28(2):523-531.
• [21]Nayak B, Kumar S, Dinapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK: Contributions of the Avian Influenza Virus HA, NA and M2 Surface Proteins to the Induction of Neutralizing Antibodies and Protective Immunity. J Virol 2009, 84(5):2408-2420.
• [22]Zhang Z, Li Y, Xu S, Chen F, Zhang L, Jiang B, Chen X: Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus. Virol J 2010, 7:89. BioMed Central Full Text
• [23]Layton SL, Kapczynski DR, Higgins S, Higgins J, Wolfenden AD, Liljebjelke KA, Bottje WG, Swayne D, Berghman LR, Kwon YM, et al.: Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poult Sci 2009, 88:2244-2252.
• [24]Lamb RA, Zebedee SL, Richardson CD: Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
• [25]Lambrecht B, Steensels M, Van Borm S, Meulemans G, van den Berg T: Development of an M2e-specific enzyme-linked immunosorbent assay for differentiating infected from vaccinated animals. Avian Dis 2007, 51:221-226.
• [26]Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
• [27]Kaiser J: A one-size-fits-all flu vaccine? Science 2006, 312:380-382.
• [28]Zhong W, He J, Tang X, Liu F, Lu X, Zeng H, Vafai A, Fu TM, Katz JM, Hancock K: Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza a viruses. J Immunol Methods 2011, 369(1-2):115-124.
• [29]Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
• [30]Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG: Comparative immunogenicity evaluations of influenza a virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
• [31]Kumar S, Koul M, Rai A: Role of immunostimulatory molecules in poultry vaccines. Recent Pat Biotechnol 2010, 4:235-241.
• [32]Santema W, van Kooten P, Hoek A, Leeflang M, Overdijk M, Rutten V, Koets A: Hsp70 vaccination-induced antibodies recognize B cell epitopes in the cell wall of Mycobacterium avium subspecies paratuberculosis. Vaccine 2011, 29:1364-1373.